Skip to main content
Sandoz Group AG logo

Sandoz Group AG — Investor Relations & Filings

Ticker · SDZ ISIN · CH1243598427 LEI · 5493000JWK6XWFEUD320 SW Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2023-10-24 Earnings Release
Country CH Switzerland
Listing SW SDZ

About Sandoz Group AG

https://www.sandoz.com/

Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.

Recent filings

Filing Released Lang Actions
Sandoz reports year-to-date sales for the first nine months of 2023
Earnings Release Classification · 100% confidence The document is titled 'Ad hoc announcement' and provides key financial highlights for the 'Nine-month' period ending September 30, 2023 (9M 2023). It details net sales, performance by business segment (Generics and Biosimilars), regional sales, and reiterates full-year guidance. This structure—a brief announcement summarizing period results before a full report—is characteristic of an Earnings Release (ER). Although it mentions the spin-off and strategic milestones, the core focus is the nine-month sales performance announcement. It is not a full, comprehensive report (like 10-K or IR), nor is it a transcript (CT) or a presentation (IP). Since it is the initial announcement of period results, ER is the most appropriate classification. 9M 2023
2023-10-24 English
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
Regulatory Filings Classification · 100% confidence The document is a press release dated October 4, 2023, announcing the successful completion of the spin-off from Novartis and the first day of trading for Sandoz shares on the SIX Swiss Exchange. It discusses strategic levers, leadership commentary, and provides contact information for Media and Investor Relations. This type of announcement, detailing a major corporate event (spin-off/listing) and providing key highlights immediately, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy (DEF 14A), and it functions as the initial public announcement of a significant corporate milestone, 'Earnings Release' (ER) is the closest fit among the provided options for a major corporate event announcement, although 'Regulatory Filings' (RNS) is also plausible. Given the focus on the successful completion of the spin-off and the start of trading, which is a major corporate event often accompanied by financial context (even if brief), ER is selected as the primary classification for this type of market-moving news release. The document length (6540 chars) is substantial enough to be more than just a brief 'Report Publication Announcement' (RPA).
2023-10-04 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.